Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who have advanced Parkinson's disease with serious, frequent changes in movement control and involuntary movements
- People for whom the treating doctor has already decided to start treatment with LECIGON® based on the official prescribing guidelines for that medication
- People who have previously been treated with a medication called subcutaneous foslevodopa (foslevodopa-foscarbidopa) for at least one month
- People (or their legal representative) who have signed a consent form agreeing to take part in the study
Who may not be able to join:
- People who have any medical reasons that the official LECIGON® prescribing guidelines say make that medication unsuitable for them
- People who will not be able to return to the trial site for follow-up appointments after starting LECIGON® treatment
- People for whom the use of the medication pump is expected to cause problems — for example, those with a serious acute illness, those unable to manage pump-based treatment, or those where severe dementia, agitation, or alcohol use may affect safe use of the pump (confirm with trial site)
- People who are already taking part in another interventional clinical trial at the same time
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bharat Amlani, MPharm, Britannia Pharmacetuicals
Phone: +44 07954751548
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from Baseline in the Reduction in OFF time (h/day) as Measured by Movement Disorder Society-unified Parkinson's Disease Rating Scale, Part IV (MDS-UPDRS IV) at 12 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.